Leeds Teaching Hospital
Welcome,         Profile    Billing    Logout  
 28 Trials 
37 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Minton, Jane
NCT03696160: The Late Presenter Treatment Optimisation Study

Completed
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus)

Completed
N/A
1000
Europe, US, RoW
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
08/24
08/24
Cross, Helen
ETX-DS-005, NCT06283212: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

Recruiting
1/2
4
Europe
ETX101
Encoded Therapeutics
Dravet Syndrome
12/29
12/29
KIK-AS, NCT04259281: A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Active, not recruiting
1/2
74
Europe, Canada, US, RoW
GTX-102
Ultragenyx Pharmaceutical Inc
Angelman Syndrome
12/24
12/24
MAST, NCT04383028: MELD as an Adjunct for SEEG Trajectories

Recruiting
N/A
20
Europe
MELD algorithm use to aid in the planning of SEEG electrode trajectories
Great Ormond Street Hospital for Children NHS Foundation Trust
Epilepsy, Epilepsy, Focal, Epilepsy, Refractory
04/22
05/22
NCT03857607: Natural History Study of ATP1A3-related Disease

Recruiting
N/A
100
Europe
Whole exome sequencing
Institute of Child Health, Great Ormond Street Hospital for Children NHS Foundation Trust, University College, London
ATP1A3-related Disease, Alternating Hemiplegia of Childhood, Rapid Onset Dystonia Parkinsonism, CAPOS
12/22
08/23
Wood, Mark D
PedVas, NCT02006134: Pediatric Vasculitis Initiative

Recruiting
N/A
1600
Europe, Canada, US, RoW
University of British Columbia, BC Childrens Hospital Research Institute, University of Oxford
Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis
03/25
03/25
Contact, Central
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed
4
52
RoW
Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT)
Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer
02/24
02/24
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Completed
3
395
RoW
Enzalutamide, Xtandi, MDV3100, Placebo
Astellas Pharma Inc
Progressive Metastatic Prostate Cancer
09/15
07/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Terminated
3
1370
Europe, US, RoW
BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo
CSL Behring
Traumatic Injury
10/24
10/24
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

Active, not recruiting
2
100
RoW
Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU
Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers
07/15
05/18
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Active, not recruiting
2
152
RoW
Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA)
Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer
Solid Tumors, Colorectal Cancer
04/18
09/18
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Active, not recruiting
2
100
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
11/24
12/24
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Recruiting
2
200
US
Sunobinop, V117957, Placebo to match sunobinop
Imbrium Therapeutics, Purdue Pharma LP
Alcohol Use Disorder
07/25
07/25
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Active, not recruiting
1
44
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Interstitial Cystitis/Bladder Pain Syndrome
06/26
06/26
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Completed
1
28
Europe, US
CSL889
CSL Behring
Sickle Cell Disease
07/23
07/23
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Checkmark Comparison of subcutaneous talazoparib versus oral talazoparib
Feb 2018 - Feb 2018: Comparison of subcutaneous talazoparib versus oral talazoparib
Withdrawn
1
10
RoW
Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib
Center Trials & Treatment, BioGene Pharmaceutical
Advanced or Recurrent Solid Tumors, Breast Neoplasm
12/23
01/24
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
12/24
04/25
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Recruiting
1
175
US
ASP4396
Astellas Pharma Inc
Solid Tumor
04/27
04/27
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Recruiting
1
21
RoW
ASP2802, MACT, MA-20, ASP101G, MicAbody
Astellas Pharma Global Development, Inc.
B-cell Lymphoma
06/26
08/31
NCT06171178: A Study of ASP1012 in Adults With Solid Tumors

Recruiting
1
229
US
ASP1012, Pembrolizumab
Astellas Pharma Global Development, Inc.
Solid Tumor
06/29
06/29
NCT06024642: Study of V117957 in Overactive Bladder Syndrome

Completed
1
51
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Overactive Bladder Syndrome
05/24
05/24
NCT03292887: Hunter Outcome Survey (HOS)

Completed
N/A
1443
US
Shire
Hunter Syndrome
02/23
02/23
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus

Terminated
N/A
2432
US, RoW
Center Trials & Treatment, Oleg Martynenko
COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE)
03/23
03/23
NCT03291223: Gaucher Disease Outcome Survey (GOS)

Recruiting
N/A
1257
US
Shire
Gaucher Disease
01/25
01/25
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Recruiting
N/A
1000
US
Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Astellas Pharma Global Development, Inc.
Hot Flashes
02/26
11/26
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Recruiting
N/A
3000
Japan
Peficitinib, ASP015K, Smyraf
Astellas Pharma Inc
Rheumatoid Arthritis (RA)
12/25
12/25
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

Active, not recruiting
N/A
249
RoW
Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens
HOYA Lens Thailand LTD.
Myopia
05/26
05/27
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting
N/A
202
RoW
Enfortumab Vedotin, PADCEV, ASG-22CE
Astellas Pharma Korea, Inc., Seagen Inc.
Urothelial Cancer
07/27
07/27
CPEVLN, NCT04792632: Clinical Performance Evaluation of Veye Lung Nodules

Recruiting
N/A
350
US
Veye Lung nodules
Aidence
Lung; Node
07/21
07/21
McKibbin, Martin
NCT04312672 / 2018-000425-31: Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruiting
1/2
42
Europe, US
AAV5-hRKp.RPGR
Janssen Research & Development, LLC, MeiraGTx UK II Ltd, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
11/26
11/26
Hughes, Stephanie
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
Kamdar, Ravi
PROTECT-UP, NCT06052475: Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

Recruiting
N/A
155
Europe
Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing), Continued RV Pacing (Right Ventricular Pacing)
Imperial College London
Pacing-Induced Cardiomyopathy, Heart Failure
05/26
08/26
PROTECT-HF, NCT05815745: "Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment"

Recruiting
N/A
2600
Europe
Pacemaker - Physiological pacing, Pacemaker - Right Ventricular pacing
Imperial College London, British Heart Foundation
Bradycardia, Pacing, Right Ventricular Pacing, His Bundle Pacing, Left Bundle Branch Area Pacing
12/29
12/29
Barman, Palash
PROTECT-HF, NCT05815745: "Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment"

Recruiting
N/A
2600
Europe
Pacemaker - Physiological pacing, Pacemaker - Right Ventricular pacing
Imperial College London, British Heart Foundation
Bradycardia, Pacing, Right Ventricular Pacing, His Bundle Pacing, Left Bundle Branch Area Pacing
12/29
12/29

Download Options